Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alkermes, Inc.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of schizophrenia according to DSM-IV-TR criteria
Has been able to achieve outpatient status for more than 3 months in the past year
Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)
Resides in a stable living situation
Willing and able to be confined to an inpatient study unit for 2 weeks or longer
You may not be if
History of poor or inadequate clinical response to treatment with aripiprazole
History of treatment resistance
Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol)
Diagnosis of current substance dependence (including alcohol)
Pregnant, lactating, or breastfeeding
Receipt of any antipsychotic medication by IM injection within 60 days before Screening
Current involuntary hospitalization or incarceration
Hospitalized for more than 30 days during the 90 days before Screening
Clareo Health | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
